Between 2011 and 2016, the Affordable Medicines Facility-Malaria (AMFm) subsidy program substantially increased access to WHO prequalified artemisinin combination therapies (ACTs) through Africa’s private sector pharmacies and drug-sellers. While the program was rigorously and extensively evaluated,...

Countries restrict the overall extent of international travel and migration to balance the expected costs and benefits of mobility. Given the ever-present threat of new, future pandemics, how should permanent restrictions on mobility respond?

The SARS-COV-2/COVID-19 pandemic has created an unprecedented public health challenge, spurring a global race to develop and distribute viable vaccines. By mid-2021, there will likely be multiple licensed vaccines. Although there is an urgent need for these vaccines to be made available, several cri...

In a recent CGD note, “Empathy and Client Relationships in Development Finance,” we emphasised the importance of development finance institutions (DFIs) investing in face-to-face contact and dialogue with their clients to build the empathetic relationships needed to deliver development outcomes. But...

Around the world, procurement processes—which are vital to ensuring an affordable, reliable, and high-quality supply of health products—remain fraught with obstacles.

On Wednesday, September 23, CGD Senior Fellow Prashant Yadav appeared before the United States International Trade Commission (USITC) at a virtual hearing examining “COVID-19 Related Goods: The U.S. Industry, Market, Trade, and Supply Chain Challenges.” His testimony focused on trade and s...